US Bancorp’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

US Bancorp’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-109	Closed	-$5K	–	3999
2020 Q1	$5K	Sell	109 -112	-51%	-$5.21K	﹤0.01%	3293
2019 Q4	$10K	Sell	221 -488	-69%	-$21.6K	﹤0.01%	3121
2019 Q3	$16K	Buy	709 +180	+34%	+$5.33K	﹤0.01%	2939
2019 Q2	$16K	Buy	529 +95	+22%	+$2.18K	﹤0.01%	2968
2019 Q1	$9K	Buy	+434	New	+$9.33K	﹤0.01%	3108

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

US Bancorp's RARX Position: Q2 2020 in Review

US Bancorp sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 109 shares — an estimated $5K sold.

US Bancorp first reported a position in RARX in Q1 2019 and held it in 5 quarters. The position peaked at $16K in Q3 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

US Bancorp reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
US Bancorp sold 109 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $5K.
US Bancorp first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 5 quarters.
US Bancorp's Ra Pharmaceuticals, Inc. Common Stock position peaked at $16K in Q3 2019.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on US Bancorp's 13F filing for Q2 2020, filed 7 Aug 2020.